Gunderson Dettmer Advises Vir Biotechnology on $150 Million Public Offering of Common Stock
Gunderson Dettmer represented Vir Biotechnology, a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol “VIR,” in a $150 million underwritten public offering of its common stock.
The offering closed on November 16, 2026. Leerink Partners, Morgan Stanley and Evercore ISI acted as bookrunning managers for the offering. Raymond James acted as co-manager for the offering.
The Gunderson deal team was led by Alexa Belonick and included Daniel Reichert, Hannah Pastore, Lydia Wang, Scott Paraker, and Jace Clegg.
